Reinforcing the social compromise of accelerated approval
- PMID: 29970919
- DOI: 10.1038/s41571-018-0066-3
Reinforcing the social compromise of accelerated approval
Comment on
-
Fulfillment of Postmarketing Requirements to the FDA for Therapies Granted Oncology Indications Between 2011 and 2016.JAMA Oncol. 2018 Jul 1;4(7):993-994. doi: 10.1001/jamaoncol.2018.0610. JAMA Oncol. 2018. PMID: 29801111 Free PMC article.
Similar articles
-
Does $760 m a year of industry funding affect the FDA's drug approval process?BMJ. 2014 Aug 5;349:g5012. doi: 10.1136/bmj.g5012. BMJ. 2014. PMID: 25096994 No abstract available.
-
Reevaluating the accelerated approval process for oncology drugs.Clin Cancer Res. 2013 Jun 1;19(11):2804-9. doi: 10.1158/1078-0432.CCR-13-0315. Epub 2013 Apr 3. Clin Cancer Res. 2013. PMID: 23553847
-
Oncology pharmaceutical funding in New Zealand: a different approach and a proposal.J Oncol Pract. 2015 May;11(3):249-51. doi: 10.1200/JOP.2014.000083. Epub 2015 Mar 31. J Oncol Pract. 2015. PMID: 25829524 No abstract available.
-
Accelerated approval of oncology products: the food and drug administration experience.J Natl Cancer Inst. 2011 Apr 20;103(8):636-44. doi: 10.1093/jnci/djr062. Epub 2011 Mar 21. J Natl Cancer Inst. 2011. PMID: 21422403 Review.
-
Drug Development, Trial Design, and Endpoints in Oncology: Adapting to Rapidly Changing Science.Clin Pharmacol Ther. 2017 May;101(5):572-574. doi: 10.1002/cpt.623. Epub 2017 Apr 4. Clin Pharmacol Ther. 2017. PMID: 28074476 Review.
Cited by
-
Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe.Clin Pharmacol Ther. 2020 Aug;108(2):350-357. doi: 10.1002/cpt.1835. Epub 2020 Apr 20. Clin Pharmacol Ther. 2020. PMID: 32236959 Free PMC article.
-
Effective delivery of Complex Innovative Design (CID) cancer trials-A consensus statement.Br J Cancer. 2020 Feb;122(4):473-482. doi: 10.1038/s41416-019-0653-9. Epub 2020 Jan 6. Br J Cancer. 2020. PMID: 31907370 Free PMC article. Review.
-
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab.Drugs. 2024 Dec;84(12):1579-1601. doi: 10.1007/s40265-024-02111-7. Epub 2024 Nov 13. Drugs. 2024. PMID: 39538109 Free PMC article. Review.
-
The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints.Biomedicines. 2022 Nov 6;10(11):2827. doi: 10.3390/biomedicines10112827. Biomedicines. 2022. PMID: 36359347 Free PMC article. Review.
-
Pre-approval and post-approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs.Br J Clin Pharmacol. 2022 May;88(5):2169-2179. doi: 10.1111/bcp.15141. Epub 2022 Jan 5. Br J Clin Pharmacol. 2022. PMID: 34779004 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources